Login Register Cart 0
Generic placeholder image

Current Aging Science

Editor-in-Chief

ISSN (Print): 1874-6098
ISSN (Online): 1874-6128

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases

Author(s): Alon Seifan, Christine A. Ganzer*, Krista Ryon, Michael Lin, Rahman Mahmudur, Henriquez Adolfo, Cindy Shih, Alan R. Jacobs, Molly Greenwald and Richard S. Isaacson

Volume 11, Issue 4, 2018

Page: [242 - 249] Pages: 8

DOI: 10.2174/1874609812666190204094233

Abstract

Background: Prodromal Neurodegenerative Disease (ND) due to tauopathies such as Alzheimer’s Disease (AD) and Synucleinopathies (SN) such as Parkinson's Disease (PD) and Dementia with Lewy Bodies (DLB) present subtly. Although ND are considered cognitive disorders, in fact ND present with behavioral and even medical symptomatology years to decades prior to the onset of cognitive changes. Recognizing prodromal ND syndromes is a public health priority because ND is common, disabling and expensive. Diagnosing prodromal ND in real world clinical settings is challenging because ND of the same pathology can present with different symptoms in different people. Individual variability in nature and variability in nurture across the life course influence how ND pathology manifests clinically. The objective of this study was to describe how non-cognitive symptoms from behavioral, medical, neurological and psychiatric domains cluster in prodromal and early stages of ND.

Methods: This was an observational study of patients receiving routine clinical care for memory disorders. All patients receiving a standardized evaluation including complete neurological history and examination and standardized brief neuropsychological testing. A Principal Component Analysis (PCA) considering emotion, motor, sensory and sleep factors was performed on the entire sample of patients in order to identify co-occurring symptom clusters. All patients received a consensus diagnosis adjudicated by at least two dementia experts. Patients were grouped into Cognitively Normal, Detectable Cognitive Impairment, and Mild Cognitive Impairment categories due to AD and/or PD/LBD or NOS pathology. Symptom cluster scores were compared between clinical diagnostic groups.

Results: In this study 165 patients completed baseline neuropsychological testing and reported subjective measures of non-cognitive symptoms. Four syndrome specific symptom factors emerged and eight non-specific symptom factors. Symptoms of personality changes, paranoia, hallucinations, cravings, agitation, and changes in appetite grouped together into a cluster consistent with an "SN Non-motor Phenotype". Appetite, walking, balance, hearing, increased falls, and dandruff grouped together into a cluster consistent with an "SN Motor Phenotype". The Prodromal AD phenotype included symptoms of anxiety, irritability, apathy, sleep disturbance and social isolation. The fourth factor included symptoms of increased sweating, twitching, and tremor grouped into a cluster consistent with an Autonomic phenotype.

Conclusion: Non-cognitive features can be reliably measured by self-report in busy clinical settings. Such measurement can be useful in distinguishing patients with different etiologies of ND. Better characterization of unique, prodromal, non-cognitive ND trajectories could improve public health efforts to modify the course of ND for all patients at risk.

Keywords: Non-cognitive, neurodegenerative, Alzheimer’s disease, self-report, mild cognitive impairment, dementia.

« Previous Next »
Graphical Abstract

[1]
Gordon BA, Blazey T, Su Y, et al. Longitudinal beta-amyloid deposition and hippocampal volume in preclinical alzheimer disease and suspected non-alzheimer disease pathophysiology. JAMA Neurol 2016; 73(10): 1192-200.
[2]
Frisoni GB, Winblad B, O’Brien JT. Revised NIA-AA criteria for the diagnosis of Alzheimer’s disease: A step forward but not yet ready for widespread clinical use. Int Psychogeriatr 2011; 23(8): 1191-6.
[3]
Krell-Roesch J, Ruider H, Lowe VJ, et al. FDG-PET and neuropsychiatric symptoms among cognitively normal elderly persons: The mayo clinic study of aging. J Alzheimers Dis 2016; 53(4): 1609-16.
[4]
Burke SL, Maramaldi P, Cadet T, et al. Associations between depression, sleep disturbance, and apolipoprotein E in the development of Alzheimer’s disease: Dementia. Int Psychogeriatr 2016; 28(9): 1409-24.
[5]
Ju YE, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. JAMA Neurol 2013; 70(5): 587-93.
[6]
Elbaz A. Prodromal symptoms of Parkinson’s disease: Implications for epidemiological studies of disease etiology. Rev Neurol (Paris) 2016; 172(8-9): 503-11.
[7]
Barnes DE, Yaffe K, Byers AL, et al. Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 2012; 69(5): 493-8.
[8]
Postuma R, Daniela B, Matthew S, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 2015; 30(12): 1591-601.
[9]
Chiba Y, Fujishiro H, Iseki E, et al. Retrospective survey of prodromal symptoms in dementia with Lewy bodies: Comparison with Alzheimer’s disease. Dement Geriatr Cogn Disord 2012; 33(4): 273-81.
[10]
Ganesh MB, Nupur G, Denise H, et al. Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. Am J Geriatr Psychiatry 2016; 24(11): 1095.
[11]
Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: Pre-motor disorders in Parkinson’s disease. Mov Disord 2012; 27(5): 617-26.
[12]
Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology. Neurology 2018; 90(3): 126-35.
[13]
Whalley LJ, Dick FD, McNeill G, et al. A life-course approach to the aetiology of late-onset dementias. Lancet Neurol 2006; 5(1): 87-96.
[14]
Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement 2016; 12(2): 195-202.
[15]
Clelia P, Dario B, Vincenzo P, et al. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr Dis Treat 2007; 3(1): 145-52.
[16]
Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study. Lancet Neurol 2015; 14(1): 57-64.
[17]
Takizawa C, Thompson PL, van Walsem A, et al. Epidemiological and economic burden of Alzheimer’s disease: A systematic literature review of data across Europe and the United States of America. J Alzheimers Dis 2015; 43(4): 1271-84.
[18]
Snyder HM, Hendrix J, Bain LJ, et al. Alzheimer’s disease research in the context of the national plan to address Alzheimer’s disease. Mol Aspects Med 2015; 43-44: 16-24.
[19]
Broderick JE, DeWitt EM, Rothrock N, et al. Advances in Patient-Reported Outcomes: The NIH PROMIS((R)) Measures. EGEMS (Wash DC) 2013; 1(1): 1015. p
[20]
Chung F, Yegneswaran B, Liao P, et al. Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. J Am Soc Anesthesiol 2008; 108(5): 822-30.
[21]
Ezzati A, Jiang J, Katz MJ, et al. Validation of the perceived stress scale in a community sample of older adults. Int J Geriatr Psychiatry 2014; 29(6): 645-52.
[22]
Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis. J Affect Disord 2016; 190: 264-71.
[23]
Golimstok A, Rojas J, Romano M, et al. Previous adult attention-deficit and hyperactivity disorder symptoms and risk of dementia with Lewy bodies: A case-control study. Eur J Neurol 2011; 18(1): 78-84.
[24]
Lee HM, Koh SB. Many Faces of Parkinson’s disease: Non-motor symptoms of Parkinson’s disease. J Mov Disord 2015; 8(2): 92-7.
[25]
Seifan A, Assuras S, Huey ED, et al. Childhood learning disabilities and atypical dementia: A retrospective chart review. PLoS One 2015; 10(6): e0129919.
[26]
Cockrell J, Folstein M. Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988; 24(4): 689.
[27]
Mack WJ, Freed DM, Williams BW, et al. Boston Naming Test: shortened versions for use in Alzheimer’s disease. J Gerontol 1992; 47(3): 154-P8.
[28]
Tombaugh TN. Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol 2004; 19(2): 203-14.
[29]
Schmidt M. Rey auditory verbal learning test: A handbook 1996: Western Psychological Services Los Angeles, CA
[30]
Weintraub S, Dikmen SS, Heaton RK, et al. The cognition battery of the NIH toolbox for assessment of neurological and behavioral function: Validation in an adult sample. J Int Neuropsychol Soc 2014; 20(6): 567-78.
[31]
McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005; 65(12): 1863-72.
[32]
Alberta MS, Steven TD, Dennis D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 270-9.
[33]
McKhann GM, David SK, Howard C. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 263-9.
[34]
Gomperts SN. Lewy body dementias: Dementia with lewy bodies and parkinson disease dementia. Continuum (Minneap Minn), 2016. 22(2 Dementia): p. 435-63.
[35]
Szeto JY, Mowszowski L, Gilat M, et al. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson’s disease. Parkinsonism Relat Disord 2015; 21(1): 31-5.
[36]
Seifan A, Schelke M, Obeng-Aduasare Y, et al. Early life epidemiology of Alzheimer’s disease-a critical review. Neuroepidemiology 2015; 45(4): 237-54.
[37]
Maria TP, Riccardo S, Marcello M, et al. Lower serum uric acid is associated with mild cognitive impairment in early Parkinson’s disease: A 4-year follow-up study. J Neural Transm (Vienna) 2016; 123(12): 1399-402.
[38]
Delgado‐Alvarado M, Belén G, Navalpotro‐Gomez I, et al. Biomarkers for dementia and mild cognitive impairment in Parkinson’s disease. Mov Disord 2016; 31(6): 861-81.
[39]
Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease: A longitudinal analysis. Neurology 2015; 84(6): 617-22.
[40]
Claassen DO, Josephs KA, Ahlskog JE, et al. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology 2010; 75(6): 494-9.
[41]
Bensamoun D, et al. Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis 2015; 49(2): 387-98.
[42]
Danna J, Andrew S, Matthew S, et al. Imaging prodromal Parkinson disease: The parkinson associated risk syndrome study. Neurology 2014; 83(19): 1739-46.
[43]
Edmonds EC, Delano-Wood L, Clark LR, et al. Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimers Dement 2015; 11(4): 415-24.
[44]
Edmonds EC, Delano-Wood L, Jak AJ, et al. “Missed” mild cognitive impairment: High false-negative error rate based on conventional diagnostic criteria. J Alzheimers Dis 2016; 52(2): 685-91.
[45]
Seifan A, Isaacson RI. The Alzheimer’s prevention clinic at weill cornell medicine: Risk stratification and early intervention. J Prev Alzheimers Dis 2015; 2(4): 254-66.
[46]
Vos SJB, Gordon BA, Su Y, et al. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging 2016; 44: 1-8.
[47]
Tiia N, Jenni L, Alina S, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): A randomised controlled trial. Lancet 2015; 385(9984): 2255-63.
[48]
Sevigny J. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature 2016; 537(7618): 50-6.

Rights & Permissions Print Cite
Article Metrics
62
8
© 2024 Bentham Science Publishers | Privacy Policy